MX2018011379A - Tratamiento del prurito uremico. - Google Patents

Tratamiento del prurito uremico.

Info

Publication number
MX2018011379A
MX2018011379A MX2018011379A MX2018011379A MX2018011379A MX 2018011379 A MX2018011379 A MX 2018011379A MX 2018011379 A MX2018011379 A MX 2018011379A MX 2018011379 A MX2018011379 A MX 2018011379A MX 2018011379 A MX2018011379 A MX 2018011379A
Authority
MX
Mexico
Prior art keywords
treatment
uremic pruritus
pruritus
uremic
patient
Prior art date
Application number
MX2018011379A
Other languages
English (en)
Inventor
Sciascia Thomas
Good Jennifer
Hawi Amale
Original Assignee
Trevi Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trevi Therapeutics Inc filed Critical Trevi Therapeutics Inc
Publication of MX2018011379A publication Critical patent/MX2018011379A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La presente invención se refiere a métodos para tratar el prurito urémico con composiciones antipruríticas, en donde el método proporciona un efecto terapéutico en un paciente.
MX2018011379A 2016-03-21 2017-03-21 Tratamiento del prurito uremico. MX2018011379A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662311134P 2016-03-21 2016-03-21
US201662412584P 2016-10-25 2016-10-25
PCT/US2017/023398 WO2017165409A1 (en) 2016-03-21 2017-03-21 Treatment of uremic pruritus

Publications (1)

Publication Number Publication Date
MX2018011379A true MX2018011379A (es) 2019-06-13

Family

ID=59899743

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018011379A MX2018011379A (es) 2016-03-21 2017-03-21 Tratamiento del prurito uremico.

Country Status (10)

Country Link
US (1) US20180008592A1 (es)
EP (1) EP3432871B1 (es)
JP (2) JP2019509309A (es)
KR (1) KR20180120756A (es)
CN (1) CN109310656A (es)
AU (1) AU2017238051B9 (es)
BR (1) BR112018069174A2 (es)
CA (1) CA3017374A1 (es)
MX (1) MX2018011379A (es)
WO (1) WO2017165409A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3105680A1 (en) * 2018-07-11 2020-01-16 Trevi Therapeutics, Inc. Treatment of the pruritic symptoms of liver disease
MX2021000908A (es) 2018-07-23 2021-06-08 Trevi Therapeutics Inc Tratamiento de la tos cronica, la dificultad respiratoria y la disnea.
WO2021222886A1 (en) * 2020-05-01 2021-11-04 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods to treat polycystic kidney disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1291717C (zh) * 1996-11-25 2006-12-27 东丽株式会社 止痒药物
WO2009047562A1 (en) * 2007-10-08 2009-04-16 Serentis Limited Methods and compositions for the treatment of pruritus
US8686040B2 (en) * 2008-03-31 2014-04-01 Rdd Pharma Ltd. Method for treating anal pruritis and other perianal disorders
US8637538B1 (en) * 2012-12-14 2014-01-28 Trevi Therapeutics, Inc. Methods for treatment of pruritis
US8987289B2 (en) * 2012-12-14 2015-03-24 Trevi Therapeutics, Inc. Methods for treating pruritus
KR20150093702A (ko) * 2012-12-14 2015-08-18 트레비 테라퓨틱스, 인코포레이티드 소양증을 치료하는 방법
AU2015274327A1 (en) * 2014-06-13 2017-01-05 Trevi Therapeutics, Inc. Methods for treating pruritus

Also Published As

Publication number Publication date
EP3432871A1 (en) 2019-01-30
EP3432871B1 (en) 2023-11-15
AU2017238051B2 (en) 2022-10-06
JP2019509309A (ja) 2019-04-04
AU2017238051B9 (en) 2022-11-03
JP2022081640A (ja) 2022-05-31
KR20180120756A (ko) 2018-11-06
BR112018069174A2 (pt) 2019-01-29
CN109310656A (zh) 2019-02-05
CA3017374A1 (en) 2017-09-28
US20180008592A1 (en) 2018-01-11
WO2017165409A1 (en) 2017-09-28
EP3432871A4 (en) 2019-10-30
AU2017238051A1 (en) 2018-10-04

Similar Documents

Publication Publication Date Title
PH12015502075A1 (en) Treatment of cataplexy
MX2017010150A (es) Bacterias probioticas recombinantes.
EP4282479A3 (en) Use of pridopidine to treat depression or anxiety
MY194341A (en) Method of treating a brain tumor
MX2017011374A (es) Método de tratamiento de cáncer asociado con una mutación de ras.
MX2021010460A (es) Metodo de tratamiento con tradipitant.
PH12017500933A1 (en) Sublingual administration of riluzole
EA036102B9 (ru) Терапевтические средства с углевод-опосредованной адресной доставкой
MX2019013808A (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer.
MX2017006015A (es) Composiciones para usar en el tratamiento de cancer renal.
PH12017500934A1 (en) Sublingual formulation of riluzole
SG10201804034QA (en) Methods for treating hypotension
MX2016015378A (es) Uso de eribulina en el tratamiento de cancer.
NZ722600A (en) Methods of treating mild brain injury
MX2019004804A (es) Tratamiento para el prurigo nodula.
MX2020009966A (es) Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina.
MX2018011379A (es) Tratamiento del prurito uremico.
TW201613610A (en) Use of ginsenoside M1 for treating lupus nephritis
MX2016012758A (es) Composicion hiperosmolar de acido hialuronico.
PH12016502150A1 (en) Method for treating renal cell carcimona
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.
MY198753A (en) Treatment of androgen deprivation therapy associated symptoms
MX2016002307A (es) Tratamiento para el cancer.
PH12017501872A1 (en) Methods of treating diseases
MX2017013669A (es) Composiciones para el tramiento del cancer.